Год публикации:
Все года
2018
2019
2020
Название |
Дата публикации |
Коллектив авторов |
Журнал |
DOI |
Индекс цитирования |
Ссылка на источник |
Dosage problems in children: Well-known facts and unresolved issues
|
01.01.2018 |
Mikhailova O.
Drozdov V.
Lazareva N.
Shikh E.
|
Voprosy Sovremennoi Pediatrii - Current Pediatrics |
|
0 |
Ссылка
© 2018 Voprosy Sovremennoi Pediatrii - Current Pediatrics. All rights reserved. The problem of dosing drugs at an early age is conditioned by specific metabolism of medicinal products (MP) in the child's body. Currently, there are a few clinical trials on the study of physiological characteristics in different periods of childhood and systematised data. It is still relevant to understand the characteristic differences that affect the bioavailability, distribution and excretion of MP, especially in children over one month of life. The results of such studies are necessary in order to formulate the recommendations for use of MP in children taking into account their age and compensate for the lack of data from direct clinical trials in pediatrics. The possibility of using a dose calculation method regarding the fat content of the body in different periods of childhood and the chemical properties of the substance has been discussed.
Читать
тезис
|
Novel possibilities in pharmacotherapy of patients with chronic heart failure
|
01.01.2018 |
Zhuravleva M.
Prokofiev A.
Shih E.
Yu S.
Gorodetskaya G.
|
Kardiologiya |
|
0 |
Ссылка
© 2018 Limited Liability Company KlinMed Consulting. All Rights Reserved. In this article we have described clinical pharmacology and data of clinical studies of an innovational drug valsartan + sacubitril in patients with chronic heart failure (CHF). The use of supramolecular complex valsartan + sacubitril allows to elevate quality of life and improve prognosis of patients with CHF. High efficacy of valsartan+sacubitril relative to impact on composite primary end-point (cardiovascular death + hospitalization due to CHF) was demonstrated in the clinical trial PARADIGM-HF in which it was compared with angiotensin converting enzyme inhibitor enalapril. Advantages of the use of valsartan + sacubitril for the budget were demonstrated in pharmacoeconomic studies. These advantages are maximally realized at long-term administration. Cost-efficacy of the use of valsartan+sacubitril in pharmacotherapy of CHF is comparable with that of statins in the treatment of ischemic heart disease or implantation of a cardioverter-defibrillator in prevention of sudden cardiac death. Thus, introduction of the drug into practice can be expected to reduce budget expenditures.
Читать
тезис
|